ES2386734T3 - Ácidos fenoxiacéticos como activadores de PPAR-DELTA - Google Patents

Ácidos fenoxiacéticos como activadores de PPAR-DELTA Download PDF

Info

Publication number
ES2386734T3
ES2386734T3 ES06830789T ES06830789T ES2386734T3 ES 2386734 T3 ES2386734 T3 ES 2386734T3 ES 06830789 T ES06830789 T ES 06830789T ES 06830789 T ES06830789 T ES 06830789T ES 2386734 T3 ES2386734 T3 ES 2386734T3
Authority
ES
Spain
Prior art keywords
alkyl
cycloalkyl
allyloxy
amino
methylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06830789T
Other languages
English (en)
Spanish (es)
Other versions
ES2386734T8 (es
Inventor
Per Sauerberg
Pavel Pihera
Zdenék POLIVKA
Miroslav Havranek
Ingrid Pettersson
John Patrick Mogensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
High Point Pharnaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Point Pharnaceuticals LLC filed Critical High Point Pharnaceuticals LLC
Application granted granted Critical
Publication of ES2386734T3 publication Critical patent/ES2386734T3/es
Publication of ES2386734T8 publication Critical patent/ES2386734T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
ES06830789T 2005-12-22 2006-12-21 Ácidos fenoxiacéticos como activadores de PPAR-DELTA Active ES2386734T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05112758 2005-12-22
EP05112758 2005-12-22
EP06115631 2006-06-19
EP06115631 2006-06-19
PCT/EP2006/070096 WO2007071766A2 (en) 2005-12-22 2006-12-21 Phenoxy acetic acids as ppar delta activators

Publications (2)

Publication Number Publication Date
ES2386734T3 true ES2386734T3 (es) 2012-08-28
ES2386734T8 ES2386734T8 (es) 2012-09-21

Family

ID=38055174

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06830789T Active ES2386734T3 (es) 2005-12-22 2006-12-21 Ácidos fenoxiacéticos como activadores de PPAR-DELTA

Country Status (14)

Country Link
US (8) US7943613B2 (https=)
EP (2) EP1979311B1 (https=)
JP (1) JP5054028B2 (https=)
KR (1) KR101265078B1 (https=)
CN (1) CN103224477A (https=)
AU (1) AU2006327003B2 (https=)
BR (1) BRPI0620468A2 (https=)
CA (1) CA2631390C (https=)
EA (3) EA201101084A1 (https=)
ES (1) ES2386734T3 (https=)
IL (1) IL191655A (https=)
NZ (1) NZ568488A (https=)
TW (1) TWI389878B (https=)
WO (1) WO2007071766A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8053598B2 (en) * 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2347578T3 (es) * 2004-05-05 2010-11-02 High Point Pharmaceuticals, Llc Derivados del acido fenoxiacetico como agonistas de ppar.
CN103224477A (zh) * 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
ITMI20071261A1 (it) * 2007-06-22 2008-12-23 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2013006769A (ja) * 2009-10-08 2013-01-10 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP5929109B2 (ja) * 2011-11-11 2016-06-01 デクセリアルズ株式会社 新規なエチニルベンゾフェノン化合物類又はその類縁体
DE112013006600T5 (de) * 2013-09-05 2016-04-21 Hitachi, Ltd. Speichersystem und Speichersteuerverfahren
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
GB201318886D0 (en) * 2013-10-25 2013-12-11 Givaudan Sa Improvements i or relating to organic compounds
TW202045152A (zh) * 2019-02-20 2020-12-16 美商雷內奧製藥股份有限公司 PPARẟ促效劑於治療粒線體性肌病之用途
CA3154859A1 (en) * 2019-09-20 2021-03-25 Reneo Pharmaceuticals, Inc. Use of a ppar-delta agonist in the treatment of kidney disease
AU2021312855A1 (en) * 2020-07-22 2023-03-09 Reneo Pharmaceuticals, Inc. Crystalline PPAR-delta agonist
WO2022115326A1 (en) * 2020-11-25 2022-06-02 Reneo Pharmaceuticals, Inc. Methods of making a ppar-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
CN120500333A (zh) 2023-01-29 2025-08-15 西玛贝医药公司 尿毒症瘙痒的治疗
KR20250139304A (ko) * 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2331336A1 (fr) * 1975-11-14 1977-06-10 Rolland Sa A Acides oxy-4,4' bis(phenoxy-2 alcanocarboxyliques), leurs derives et leur application comme medicament
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
IL109451A0 (en) * 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
DE69720429T9 (de) 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
EP1011651B1 (en) 1996-02-02 2005-04-27 Merck & Co., Inc. Method of treating diabetes and related disease states
EP0888278B1 (en) 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetic agents
ATE262334T1 (de) 1996-02-02 2004-04-15 Merck & Co Inc Antidiabetisches mittel
AU2652397A (en) 1996-05-13 1997-12-05 Nippon Shinyaku Co. Ltd. Substituted ethylene compounds and drugs
US5773469A (en) 1996-06-18 1998-06-30 Ortho Pharmaceutical Corporation Diaryl antimicrobial agents
WO1997048876A1 (en) 1996-06-21 1997-12-24 Smith International, Inc. Rolling cone bit having gage and nestled gage cutter elements having enhancements in materials and geometry to optimize borehole corner cutting duty
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO1998027974A1 (en) 1996-12-23 1998-07-02 Merck & Co., Inc. Antidiabetic agents
AU749271B2 (en) 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
BR9814087A (pt) 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
US6972294B1 (en) * 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
KR20020005703A (ko) 1999-04-20 2002-01-17 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 신규한 화합물, 그의 제법 및 용도
CA2374263A1 (en) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6368155B1 (en) 1999-07-16 2002-04-09 Molex Incorporated Intelligent sensing connectors
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
AU1303301A (en) 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors
PL355172A1 (en) 1999-11-11 2004-04-05 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US6555577B1 (en) * 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
AU2831901A (en) 2000-01-28 2001-08-07 Novo Nordisk A/S Propionic acid derivatives and their use in the treatment of diabetes and obesity
US6569901B2 (en) * 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
BR0107902A (pt) 2000-01-28 2002-11-05 Novo Nordisk As Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade
AU784722B2 (en) 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
KR20020081424A (ko) 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ｐｐａｒ 매개인자의 치료학적 용도
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
AU2001248279A1 (en) 2000-04-17 2001-10-30 Novo-Nordisk A/S New compounds, their preparation and use
EP1285058A2 (en) 2000-05-18 2003-02-26 Schering Aktiengesellschaft Fertilization of aged oocytes
CN1338310A (zh) 2000-08-10 2002-03-06 清华大学 一种猪瘟病毒表位疫苗及其制备方法
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
DE60129712T2 (de) * 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
US6630504B2 (en) * 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
JPWO2002046154A1 (ja) 2000-12-05 2004-04-08 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
CA2433573A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
EP1357914A2 (en) 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
JP4157381B2 (ja) 2001-03-23 2008-10-01 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体の活性化剤
WO2002079162A1 (en) 2001-03-28 2002-10-10 Eisai Co., Ltd. Carboxylic acids
JPWO2002080899A1 (ja) 2001-03-30 2005-01-06 エーザイ株式会社 消化器疾患治療剤
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2002098840A1 (en) 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
NL1018283C2 (nl) 2001-06-13 2002-12-19 Dsm Nv Werkwijze voor het in contact brengen van gesmolten ureum met een gasstroom.
FR2826574B1 (fr) 2001-06-29 2005-08-26 Oreal Compositions contenant un derive d'hydroxydiphenyl ether inhibant le developpement des odeurs corporelles
US7067530B2 (en) * 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
BR0211414A (pt) 2001-07-30 2004-08-17 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
US6869967B2 (en) * 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
JP2004536152A (ja) 2001-07-30 2004-12-02 ノボ　ノルディスク　アクティーゼルスカブ 新規ビニルｎ−（２−ベンゾイルフェニル）−ｌ−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
AU2002323776B2 (en) 2001-08-10 2008-07-31 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor Delta
WO2003016265A1 (en) 2001-08-17 2003-02-27 Eisai Co., Ltd. Cyclic compound and ppar agonist
EP1435946B8 (en) * 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
MXPA04003398A (es) 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
JP2005505616A (ja) 2001-10-17 2005-02-24 ノボ　ノルディスク　アクティーゼルスカブ ジカルボン酸誘導体、それらの調製、並びに治療上の用途
US7220877B2 (en) * 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
DE10151390A1 (de) 2001-10-18 2003-05-08 Bayer Ag Essigsäurederivate
JP2003171275A (ja) 2001-12-11 2003-06-17 Sumitomo Pharmaceut Co Ltd ＰＰＡＲδアゴニスト
ES2290439T3 (es) 2002-02-25 2008-02-16 Eli Lilly And Company Moduladores del receptor activado del proliferador de peroxisomas.
US7319104B2 (en) 2002-03-01 2008-01-15 Smithkline Beecham Corporation hPPARs activators
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
DE10222034A1 (de) 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
MXPA05000011A (es) 2002-06-26 2005-04-08 Pharmacia Corp Formulacion parenteral liquida estable de parecoxib.
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
AU2003281040A1 (en) 2002-07-10 2004-02-02 Sumitomo Pharmaceuticals Co., Ltd. Biaryl derivatives
CA2499380A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
WO2004037778A1 (en) 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Substituted tetralins and indanes
AU2003273783C1 (en) * 2002-10-28 2010-08-12 Vtv Therapeutics Llc Novel compounds and their use as PPAR-modulators
US7129268B2 (en) * 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
JP4584714B2 (ja) * 2002-10-28 2010-11-24 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規化合物、その調製および使用
US20050080115A1 (en) * 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
US7396850B2 (en) 2003-01-06 2008-07-08 Eli Lilly And Company Pyrazole derivative as PPAR modulator
DE10300099A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Indol-Phenylsulfonamid-Derivate
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物
JPWO2004080943A1 (ja) 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
CA2518986A1 (en) 2003-03-13 2004-09-23 Ono Pharmaceutical Co., Ltd. Imino ether derivative compounds and drugs containing the compounds as the active ingredient
CA2521175A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
KR100762762B1 (ko) 2003-04-17 2007-10-17 칼립시스, 인코포레이티드 Ｐｐａｒ의 조절인자로서의 아릴 화합물 및 신진대사장애의 치료 방법
MXPA05011536A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
US20070082907A1 (en) 2003-11-25 2007-04-12 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2005097096A1 (en) 2004-03-31 2005-10-20 Pharmacia & Upjohn Company Llc A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders
AU2005230838A1 (en) 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as PPAR delta
WO2005097098A2 (en) 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. Use of ppr delta agonists for treating demyelinating diseases
NZ550857A (en) 2004-04-01 2009-12-24 Aventis Pharma Inc 1,3,4-oxadiazol-2-ones as PPAR delta modulators
JPWO2005097782A1 (ja) 2004-04-07 2007-08-16 協和醗酵工業株式会社 ピペリジン誘導体
DE602005024539D1 (de) * 2004-05-05 2010-12-16 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
ES2347578T3 (es) * 2004-05-05 2010-11-02 High Point Pharmaceuticals, Llc Derivados del acido fenoxiacetico como agonistas de ppar.
US8053598B2 (en) * 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2372617T3 (es) * 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN103224477A (zh) * 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) * 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
FR2898271B1 (fr) 2006-03-09 2009-01-16 Pierre Fabre Medicament Sa Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
US20100197950A1 (en) * 2006-06-08 2010-08-05 Kaare Gyberg Rasmussen Process for preparing phenoxy acetic acid derivatives
EP3756661A1 (en) * 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy

Also Published As

Publication number Publication date
EA200870103A1 (ru) 2008-12-30
US20140024645A1 (en) 2014-01-23
EA201101084A1 (ru) 2012-04-30
US20200215073A1 (en) 2020-07-09
AU2006327003B2 (en) 2011-10-06
EP1979311B1 (en) 2012-06-13
KR20080078707A (ko) 2008-08-27
BRPI0620468A2 (pt) 2011-11-08
EA201101085A1 (ru) 2012-05-30
US7943613B2 (en) 2011-05-17
NZ568488A (en) 2011-07-29
US20180071304A1 (en) 2018-03-15
IL191655A0 (en) 2008-12-29
ES2386734T8 (es) 2012-09-21
US20110245244A1 (en) 2011-10-06
US10471066B2 (en) 2019-11-12
EP1979311A2 (en) 2008-10-15
US8551993B2 (en) 2013-10-08
KR101265078B1 (ko) 2013-05-20
US20210188758A1 (en) 2021-06-24
EP2386540A1 (en) 2011-11-16
TWI389878B (zh) 2013-03-21
IL191655A (en) 2014-06-30
CA2631390C (en) 2014-03-11
WO2007071766A3 (en) 2007-09-13
CA2631390A1 (en) 2007-06-28
US9855274B2 (en) 2018-01-02
US9663481B2 (en) 2017-05-30
JP2009520769A (ja) 2009-05-28
US20170216303A1 (en) 2017-08-03
US8362016B2 (en) 2013-01-29
WO2007071766A2 (en) 2007-06-28
US10947180B2 (en) 2021-03-16
US11420929B2 (en) 2022-08-23
JP5054028B2 (ja) 2012-10-24
US20090093484A1 (en) 2009-04-09
AU2006327003A1 (en) 2007-06-28
TW200745004A (en) 2007-12-16
US20130102610A1 (en) 2013-04-25
CN103224477A (zh) 2013-07-31
EA015717B1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
ES2386734T3 (es) Ácidos fenoxiacéticos como activadores de PPAR-DELTA
US7943612B2 (en) Compounds that modulate PPAR activity, their preparation and use
US8217086B2 (en) Phenoxy acetic acids as PPAR delta activators
AU2011253593A1 (en) Phenoxy acetic acids as PPAR delta activators
HK1125915A (en) Phenoxy acetic acids as ppar delta activators